Atrial fibrillation can lead to heart failure, and heart failure is often combined with atrial fibrillation. What is the treatment for patients with both atrial fibrillation and heart failure? This article will give you detailed answers. According to the 2014 AHA guidelines for the management of atrial fibrillation, for patients with compensated heart failure with preserved ejection fraction (HFpEF) combined with persistent or permanent atrial fibrillation, beta-blockers (such as betalactam) or non-dihydropyridine calcium channel antagonists (such as diltiazem) are recommended to control the resting heart; when atrial fibrillation is not combined with pre-excitation, intravenous beta-blockers are recommended for patients with acute heart failure to slow down the The rapid ventricular rate in atrial fibrillation, but caution is needed in heart failure patients with significant congestion, hypotension or reduced left ventricular ejection fraction. According to our 2012 expert consensus on atrial fibrillation, radiofrequency ablation can be the first-line treatment for patients with symptomatic atrial fibrillation in the presence of heart failure/reduced left ventricular ejection fraction. The above paragraph may be a bit confusing for patients to read, and involves more medical terminology. The main content is that for patients with atrial fibrillation combined with heart failure, drug control of the ventricular rate is optional, and radiofrequency ablation is also an option. In recent years, catheter ablation of atrial fibrillation in the treatment of atrial fibrillation combined with heart failure has achieved significant efficacy, and the success rate of catheter ablation of atrial fibrillation combined with heart failure is similar to that of atrial fibrillation without heart failure, while the incidence of perioperative complications is not significantly different from that of atrial fibrillation without heart failure. The PABA-CHF study, published in 2008, compared catheter ablation with atrioventricular node ablation + biventricular pacing in patients with atrial fibrillation in the setting of heart failure. In this prospective multicenter clinical trial, 81 patients with atrial fibrillation who had significant symptoms, poor pharmacologic outcomes, left ventricular ejection fraction less than 40%, and NYHA class II or III cardiac function (i.e., patients with poor cardiac function) were randomized to either the catheter ablation group or the AV node ablation + pacemaker implantation group. There was no significant difference in major complications between the two groups. At 6-month follow-up, patients in the radiofrequency ablation group had a higher quality of life, a longer 6-minute walk distance, and a higher left ventricular ejection fraction. This study shows that catheter ablation is more effective in reducing symptoms, improving quality of life and exercise tolerance, and improving cardiac function in patients with significant symptoms of atrial fibrillation combined with heart failure (LVEF ≤ 40%), and is recommended in centers experienced in catheter ablation of atrial fibrillation. In our clinical work, it is obvious that for patients with atrial fibrillation combined with heart failure, the current traditional antiarrhythmic drug therapy is not effective, while radiofrequency ablation of atrial fibrillation improves the quality of life of patients by restoring their sinus rhythm and restoring the coordination of atrial and ventricular activities, resulting in a more significant improvement of cardiac function.